[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100226079":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":24,"locations":34,"responsibleParty":77,"collaborators":24,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":24,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":24,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":99,"whyStopped":100,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ABT-957","EXPERIMENTAL","ABT-957 administered twice-daily for 7 days",[13],"Drug: ABT-957",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo administered twice-daily for 7 days",[19],"Other: Placebo for ABT-957",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"OTHER","Placebo for ABT-957","Placebo for ABT-957 administered twice-daily for 7 days",[15],[31],{"name":32,"affiliation":5,"role":33},"Nuno Mendonca, MD","STUDY_DIRECTOR",[35,48,58,67],{"facility":36,"status":24,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":24},"Site Reference ID\u002FInvestigator# 129545","Glendale","California","91206","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-118.25508,34.14251,{"lat":46,"lon":45},{"facility":49,"status":24,"city":50,"state":51,"zip":52,"country":40,"countryCode":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":24},"Site Reference ID\u002FInvestigator# 129435","Orlando","Florida","32806",{"type":43,"coordinates":54},[55,56],-81.37924,28.53834,{"lat":56,"lon":55},{"facility":59,"status":24,"city":60,"state":60,"zip":61,"country":40,"countryCode":41,"cosmosGeoPoint":62,"geoPoint":66,"contacts":24},"Site Reference ID\u002FInvestigator# 129641","New York","10019",{"type":43,"coordinates":63},[64,65],-74.00597,40.71427,{"lat":65,"lon":64},{"facility":68,"status":24,"city":69,"state":70,"zip":71,"country":40,"countryCode":41,"cosmosGeoPoint":72,"geoPoint":76,"contacts":24},"Site Reference ID\u002FInvestigator# 144825","Salt Lake City","Utah","84106",{"type":43,"coordinates":73},[74,75],-111.89105,40.76078,{"lat":75,"lon":74},{"type":78,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100226079","phase-1-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-abt-957-in-subjects-with-mild-to-moderate-alzheimers-disease-on-stable-doses-of-acetylcholinesterase-inhibitors-100226079",false,"NCT02220738","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","Inclusion Criteria:\n\n* Meets the National Institute of Neurological and Communicative Disorders and Stroke\u002FAlzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's disease (AD);\n* Has a Mini-Mental State Examination total score of 16 to 26;\n* Has a Modified Hachinski Ischemia Scale score of ≤ 4;\n* Is taking a stable dose of donepezil, galantamine or rivastigmine for at least 30 days;\n* Has had a computerized tomography or magnetic resonance imaging. The scan must not show evidence for an alternative etiology for dementia;\n* With the exception of a diagnosis of mild-to-moderate AD and the presence of stable medical conditions, is in general good health.\n\nExclusion Criteria:\n\n* Positive screen for drugs of abuse, alcohol or cotinine;\n* Females must not have positive results for pregnancy;\n* Focal neurological signs on examination;\n* Has a clinically significant abnormal value, in serum chemistry, hematology or urinalysis;\n* History of any significant neurologic disease other than AD;\n* History of head trauma, motor vehicle accident, concussion.","ALL","55 Years","90 Years",{"count":90,"type":91},19,"ACTUAL","INTERVENTIONAL",[94],"PHASE1","This study is designed to evaluate the safety, tolerability and pharmacokinetics of multiple doses of ABT-957 in subjects with mild to moderate Alzheimer's disease.",[97],"Alzheimer's Disease",[97],"TERMINATED","Slow subject enrollment","2021-07-02",{"date":103,"type":91},"2021-07-06",{"date":105,"type":24},"2014-09",{"date":107,"type":91},"2016-03",{"name":5,"class":6},4]